Resmed Inc. · NYSE:RMD
Resmed — Investor Presentation (September 2026)
16 slides from Resmed's investor presentation, September 2026
Slide 1: Resmed Stewardship Presentation
Resmed Stewardship Presentation September 2026 June 4, 2025
Slide 2: Presentation of financial information & forward-looking statements
Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc. ("Resmed"), its subsidiaries, and its legal entities for the periods indicated. This presentation includes financial informa
Slide 3: Fiscal 2026 highlights
Fiscal 2026 highlights Delivered significant free cash flow that we both invested back into the business and returned to shareholders Board of Directors is well-positioned to support management in its execution of the 2030 strategy; Carol Burt named as Lead Independent Director following retirement
Slide 4: Resmed | The global leader in connected and digital health
Resmed | The global leader in connected and digital health Corporate Highlights FY26 Financial Highlights Headquarters San Diego, CA Total HL revenue ~$5.7B 12%3 12% 3 Founded 1989 CC Revenue YoY 8% Revenue Revenue growth 37% by business 50% 30% by region Listed (NYSE, Non-GAAP FY26 FY26 58% 1995, R
Slide 5: Our 2030 Strategy
2030 OUR STRATEGY STRATEGY OUR OUR KEY FOCUS CAPABILITIES AREAS We will create products people love as well as Sleep Health seamless, personalized Empower our teams pathways for access to Breathing Health life-changing care Prioritize AI OUR OUR Health Tech at Home Build trust FINANCIAL MISSION GOAL
Slide 6: Board – overview
Board – overview Lead Director effective: November 15, 2026 Christopher DelOrefice, Michael J. Farrell, BE, SM, Carol J. Burt, BBA Jan De Witte, MSE, MBA Karen Drexler, BSE, MBA BS, MBA MBA Independent Non-Executive Independent Non-Executive Independent Non-Executive Independent Non-Executive Non-In
Slide 7: Board – committee structure
Board – committee structure Committee Member Committee Chair Chairman of the Board Financial Expert Compensation and Leadership Compliance, Nominating and Board Members Audit Development Privacy and Quality Governance Carol J. Burt, BBA | Lead Independent Director effective November 15, 2026 Christo
Slide 8: Board – oversight of strategy
Board – oversight of strategy • Board actively participates in continued evolution of Resmed’s 2030 strategy ‐ Executive leadership team regularly interacts with Board members and receives Board feedback ‐ Board also reviews Resmed's strategy annually and as needed during individual board meetings •
Slide 9: Board – key committee responsibilities
Board – key committee responsibilities Board Audit Compensation and Leadership Compliance, Privacy Nominating and Governance Committee Development Committee and Quality Committee Committee Oversees financial risk, Oversees compensation philosophy Oversees compliance with Evaluates each director’s in
Slide 10: PwC selected as Resmed's new independent registered public accounting firm
PwC selected as Resmed’s new independent registered public accounting firm • Resmed’s Audit Committee completed a competitive auditor RFP process during fiscal year 2026, evaluating multiple firms against pre-defined criteria including industry expertise, audit quality, technology capabilities, tran
Slide 11: Human capital management – overview
Human capital management – overview As of June 30, 2026, Resmed had ~11,370 employees • Resmed’s average global turnover 3,490 rate for fiscal year 2026 was 2,300 4,480 2,670 approximately 13% By By • Resmed encourages diversity of Function Geography 1,650 thought to ensure that both employees and c
Slide 12: Human capital management – experienced leadership team
Human capital management – experienced leadership team Mick Farrell Aaron Bloomer Mike Rider Vered Keisar Salli Schwartz Chief Executive Officer and Chief Financial Officer Chief Legal Officer Chief People Officer Chief Investor Relations Officer Chairman of the Board <1 year with Resmed 14 years wi
Slide 13: Executive compensation – program highlights
Executive compensation – program highlights Geographic Considerations Key Principles Resmed is headquartered in the US and the majority of our officers work and reside in To emphasize pay for performance the US. To be able to compete for best-in-industry talent in support of our growth and ensure al
Slide 14: Executive compensation – predominantly at-risk structure
Executive compensation – predominantly at-risk structure Base salary Cash incentive program Equity incentive program • Provides our • Rewards achievement of • Balanced, with 50% of grant value in long-term performance executives with a pre-established short-term units, and 50% in shorter term perfor
Slide 15: Sustainability practices – overview
Sustainability practices – overview • We aim to minimize Resmed’s environmental footprint across all operations and throughout our supply chain • We focus on designing and developing innovative products that have a lower environmental impact throughout their lifecycle • We are committed to conductin
Slide 16: Fiscal 2026 highlights
Fiscal 2026 highlights Delivered significant free cash flow that we both invested back into the business and returned to shareholders Board of Directors is well-positioned to support management in its execution of the 2030 strategy; Carol Burt named as Lead Independent Director following retirement